GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Filed today
—
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Sai Parenterals Ltd

Sai Parenterals Q2 FY27 Net Profit Rs. 105.10 Million; Completes Saicriti Pharma Acquisition

RESULTS ▲ Positive Development MEDIUM RISK
📅 Filed on BSE: 01 Nov 2026, 02:58 PM IST  ·  BSE ID: f6a964df-df59-496a-b31b-afddd4e955d8
View Original BSE Filing (PDF)
💡
In Simple Terms
The company announced its latest financial results, completed one acquisition, and will fully acquire another subsidiary soon.
🤖 AI Summary
  • Sai Parenterals reported consolidated net profit of Rs. 105.10 Million for the quarter ended September 30, 2026 (Q2 FY27).
  • The company completed the acquisition of 60% equity share capital in Saicriti Pharma Private Limited.
  • Board approved the acquisition of remaining 25% equity in SP Analytics Private Limited for Rs. 25,000/- by December 31, 2026.
  • SP Analytics Private Limited, a related party, will become a wholly-owned subsidiary with this acquisition.
  • A Management Committee was constituted for operational functioning and administration convenience.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Consolidated Revenue from Operations Q2 FY27
194.18 Million
Consolidated Net Profit Q2 FY27
105.10 Million
Consolidated Revenue from Operations H1 FY27
373.59 Million
Consolidated Net Profit H1 FY27
184.33 Million
Cost of acquiring 25% equity in SP Analytics
Rs. 25,000/-
🏢 How This Affects the Company
📈
Business Impact
The completion of Saicriti Pharma acquisition integrates its business into Sai Parenterals, while making SP Analytics a wholly-owned subsidiary enhances control over its pharmaceutical testing and analysis services.
💰
Financial Impact
Consolidated Net Profit for Q2 FY27 stands at Rs. 105.10 Million. The acquisition of 25% of SP Analytics involves a cash consideration of Rs. 25,000/-.
⚙️
Operational Impact
The constitution of a Management Committee aims to streamline company functioning and administration. Full ownership of SP Analytics facilitates unified operational control.
⚠️
Risk Impact
The acquisition of SP Analytics is a related party transaction. The filing states it is undertaken at arm’s length based on mutually agreed terms and appropriate assessment.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required by shareholders based on this filing.
👤
Who Is Affected
Shareholders are affected by the company's financial performance, including the reported Q2 FY27 consolidated net profit of Rs. 105.10 Million and the strategic acquisitions that modify the company's asset base and operational structure.
🔍
Management Signal
The management's decision to complete acquisitions and constitute a Management Committee signals a focus on consolidating business operations and improving administrative efficiency.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
Q3 FY27 financial results — observe sustained revenue and profit growth.
SP Analytics acquisition completion — confirm transaction finalization by December 31, 2026.
Saicriti Pharma integration details — monitor updates on subsidiary performance and contribution.
MEDIUM RISK The acquired SP Analytics entity has reported nil turnover over the last three financial years, presenting integration and profitability risks.
💡 Investor Takeaway
Sai Parenterals reported Q2 FY27 consolidated net profit of Rs. 105.10 Million, increasing from Rs. 63.50 Million in Q2 FY26. The acquisition of Saicriti Pharma Private Limited is completed, and the company will fully acquire SP Analytics Private Limited for Rs. 25,000/- by December 31, 2026, making it a wholly-owned subsidiary.
⚖️ Strengths & Concerns

✅ Positives

  • Consolidated Net Profit for Q2 FY27 increased to Rs. 105.10 Million compared to Rs. 63.50 Million in Q2 FY26.
  • Completion of Saicriti Pharma acquisition expands the company's operational footprint and subsidiary portfolio.

⚠️ Concerns

  • SP Analytics Private Limited, which is being fully acquired, reported nil turnover during the last three financial years.
  • Consolidated Cash Flow from Operating Activities showed a net outflow of (2054.60) Million for the half-year ended September 30, 2026.
📅 Company Track Record
Sai Parenterals was recently listed, with an IPO within the last 12 months (April 2026, based on past filing context indicating delay in Q3 FY26 results). The company sought an extension for Q3 FY26 results due to audit delays related to an acquired Australian subsidiary. Limited public track record is available.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What was Sai Parenterals Ltd's consolidated net profit for Q2 FY27?
Sai Parenterals Ltd. reported a consolidated net profit of Rs. 105.10 Million for the quarter ended September 30, 2026 (Q2 FY27).
Which acquisition has Sai Parenterals Ltd completed?
Sai Parenterals Ltd. completed the acquisition of 60% of the equity share capital of Saicriti Pharma Private Limited, making it a subsidiary.
What is the status of the SP Analytics Private Limited acquisition?
Sai Parenterals Ltd. will acquire the remaining 25% equity shareholding in SP Analytics Private Limited for Rs. 25,000/-, making it a wholly owned subsidiary by December 31, 2026.
What was the revenue from operations for Sai Parenterals Ltd in Q2 FY27?
The consolidated revenue from operations for Sai Parenterals Ltd. in Q2 FY27 was 194.18 Million.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again — explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.